Lupin’s Japanese subsidiary - Kyowa Pharmaceutical Industry Company, has entered into a strategic asset purchase agreement with Shionogi & Company to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing authorization of the products to Kyowa.
As a part of this growth strategy, Shionogi would transfer 21 long-listed products to Kyowa, the Japanese subsidiary of Lupin. Kyowa is amongst the top 10 Generic companies in Japan and a market leader in Central Nervous System (CNS) space well known for its ‘AMEL’ brand, in addition to other generic pharmaceutical products in its portfolio. With this acquisition, Kyowa will rank sixth amongst generic companies in Japan.
The 21 products cover therapy areas such as Central Nervous System (CNS), Oncology, Cardiovascular and Antiinfectives. These 21 products had sales of JPY 9,400 million ($90 million) collectively on National Health Insurance (NHI) price basis.
